2020 American Transplant Congress
HLA Specific Antibody Levels after EDTA Treatment in CDC Crossmatch Positive and Negative Sera with Known Donor-Specific Antibodies
*Purpose: Ethylenediaminetetraacetic acid (EDTA) treatment of serum samples overcomes the prozone effect that may interfere with solid phase HLA specific antibody analyses. In patients with…2020 American Transplant Congress
MHC II-Decoy Car-T Cells to Induce Long-Term Allotransplant Organ Tolerance
*Purpose: Allotransplantation represents the definitive therapy for end-stage renal, heart, liver, and lung disease. Current immunosuppressive regimens fail to promote long-term engraftment, leading to chronic…2019 American Transplant Congress
Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates
*Purpose: Evaluate anti-HLA antibody (Ab) emergence after catch-up vaccinations in pediatric kidney transplant candidates (PKTC).*Methods: A single center retrospective review of PKTC 25% from baseline,…2019 American Transplant Congress
Predicted Indirectly Recognizable H L A Epitopes Are Associated with T-cell Mediated Rejection among Kidney Transplant Recipients with Preformed and De Novo Donor-Reactive T-cells
*Purpose: Very recently Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) have been suggested to demonstrate early and late effects on kidney allograft outcomes. The association between…2019 American Transplant Congress
Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation
*Purpose: According to the latest Banff’s criteria approved in 2003, antibody mediated rejections following renal transplantation are divided into 2 types namely C4d + and…2019 American Transplant Congress
Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?
Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil
*Purpose: The reduction of anti-HLA has been proven to be efficient and safe in transplants of highly-sensitized with living donors (LD). The results of adopting…2019 American Transplant Congress
Towards Human Leukocyte Antigen Immunogenicity Assessment at the Individual Patient Level
*Purpose: Allorecognition of donor HLA and induction of humoral alloimmunity is a major cause of graft loss after solid-organ transplantation. Current approaches to study molecular…2018 American Transplant Congress
Selection and Stratification of Anti-HLA-A and HLA-B Sensitized Patients in Pig-to-Human Xenotransplantation
Introduction: Patients with anti-HLA-A and –B antibodies are difficult to match and represent a possible population for inclusion in pig-to-human xenotransplantation clinical trials. Donor specific…2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…2018 American Transplant Congress
Correlation of Kidney Transplant Human Leukocyte Antigen Eplet Mismatching to De Novo Donor Specific Antibody Production and Post-Transplant Outcomes
Human Leukocyte Antigen (HLA) eplet mismatches (EMM) are associated with the development of de novo donor specific antibody (dnDSA) in kidney transplant recipients (KTRs). There…
American Transplant Congress abstracts